OVCAR-5 Cells
USD$650.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | OVCAR-5 is a human ovarian carcinoma cell line established from the tumor of an untreated patient. This cell line serves as a robust model for studying the biology of high-grade ovarian cancers and is particularly valuable for investigating responses to platinum-based chemotherapeutics, as well as the molecular mechanisms underlying chemoresistance. OVCAR-5 has been extensively utilized in preclinical drug development and cancer biology research. OVCAR-5 cells display an epithelial morphology and grow as an adherent monolayer under standard culture conditions. Unlike other OVCAR series cell lines derived from chemoresistant patients, OVCAR-5 is derived from a chemotherapy-naive tumor, providing a baseline model for exploring intrinsic tumor properties. Notably, OVCAR-5 expresses metallothionein, a protein associated with cellular responses to heavy metals and oxidative stress, but this does not necessarily confer cisplatin resistance as observed in other cell lines of the series. The cell line has a cisplatin sensitivity profile distinct from those derived from chemoresistant patients, with an IC50 value of 0.61 μM for cisplatin. In research, OVCAR-5 is used to screen novel chemotherapeutics, evaluate targeted therapies, and study combinations of drugs aimed at improving treatment outcomes for ovarian carcinoma. It is also employed in exploring the genetic and epigenetic landscapes of high-grade ovarian cancers, including DNA damage repair pathways, signaling networks, and the tumor microenvironment. OVCAR-5 remains an important tool for advancing the understanding and treatment of ovarian cancer. |
|---|---|
| Organism | Human |
| Tissue | Ascites |
| Disease | Ovarian adenocarcinoma |
| Metastatic site | Ascites |
| Synonyms | OVCAR 5, NIH:OVCAR-5, OVCAR.5, OVCAR5, Ovcar5, OVCA5 |
Characteristics
| Age | 67 years |
|---|---|
| Gender | Female |
| Ethnicity | Caucasian |
| Growth properties | Adherent |
Regulatory Data
| Citation | OVCAR-5 (Cytion catalog number 305616) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_1628 |
Biomolecular Data
| Mutational profile | Mutation: KRAS, Simple, p.Gly12Val (c.35G>T), Homozygous |
|---|
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Dissociation Reagent | Accutase |
| Doubling time | 27 hours |
| Fluid renewal | 2 to 3 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305616-040425 | Certificate of Analysis | 26. May. 2025 | 305616 |